335 related articles for article (PubMed ID: 22638872)
1. Physiologically based modeling of pravastatin transporter-mediated hepatobiliary disposition and drug-drug interactions.
Varma MV; Lai Y; Feng B; Litchfield J; Goosen TC; Bergman A
Pharm Res; 2012 Oct; 29(10):2860-73. PubMed ID: 22638872
[TBL] [Abstract][Full Text] [Related]
2. Assessment of OATP transporter-mediated drug-drug interaction using physiologically-based pharmacokinetic (PBPK) modeling - a case example.
Chen Y; Zhu R; Ma F; Mao J; Chen EC; Choo EF; Sahasranaman S; Liu L
Biopharm Drug Dispos; 2018 Nov; 39(9):420-430. PubMed ID: 30335192
[TBL] [Abstract][Full Text] [Related]
3. Mechanistic modeling to predict the transporter- and enzyme-mediated drug-drug interactions of repaglinide.
Varma MV; Lai Y; Kimoto E; Goosen TC; El-Kattan AF; Kumar V
Pharm Res; 2013 Apr; 30(4):1188-99. PubMed ID: 23307347
[TBL] [Abstract][Full Text] [Related]
4. Physiologically Based Pharmacokinetic Modeling of Rosuvastatin to Predict Transporter-Mediated Drug-Drug Interactions.
Hanke N; Gómez-Mantilla JD; Ishiguro N; Stopfer P; Nock V
Pharm Res; 2021 Oct; 38(10):1645-1661. PubMed ID: 34664206
[TBL] [Abstract][Full Text] [Related]
5. Physiologically Based Pharmacokinetic Models for Prediction of Complex CYP2C8 and OATP1B1 (SLCO1B1) Drug-Drug-Gene Interactions: A Modeling Network of Gemfibrozil, Repaglinide, Pioglitazone, Rifampicin, Clarithromycin and Itraconazole.
Türk D; Hanke N; Wolf S; Frechen S; Eissing T; Wendl T; Schwab M; Lehr T
Clin Pharmacokinet; 2019 Dec; 58(12):1595-1607. PubMed ID: 31129789
[TBL] [Abstract][Full Text] [Related]
6. Investigating Transporter-Mediated Drug-Drug Interactions Using a Physiologically Based Pharmacokinetic Model of Rosuvastatin.
Wang Q; Zheng M; Leil T
CPT Pharmacometrics Syst Pharmacol; 2017 Apr; 6(4):228-238. PubMed ID: 28296193
[TBL] [Abstract][Full Text] [Related]
7. Physiologically Based Pharmacokinetic Modeling of Transporter-Mediated Hepatic Disposition of Imaging Biomarker Gadoxetate in Rats.
Scotcher D; Melillo N; Tadimalla S; Darwich AS; Ziemian S; Ogungbenro K; Schütz G; Sourbron S; Galetin A
Mol Pharm; 2021 Aug; 18(8):2997-3009. PubMed ID: 34283621
[TBL] [Abstract][Full Text] [Related]
8. Prediction of drug-drug interaction potential mediated by transporters between dasatinib and metformin, pravastatin, and rosuvastatin using physiologically based pharmacokinetic modeling.
Chang M; Bathena S; Christopher LJ; Shen H; Roy A
Cancer Chemother Pharmacol; 2022 Mar; 89(3):383-392. PubMed ID: 35147740
[TBL] [Abstract][Full Text] [Related]
9. Prediction of the Pharmacokinetics of Pravastatin as an OATP Substrate Using Plateable Human Hepatocytes With Human Plasma Data and PBPK Modeling.
Mao J; Doshi U; Wright M; Hop CECA; Li AP; Chen Y
CPT Pharmacometrics Syst Pharmacol; 2018 Apr; 7(4):251-258. PubMed ID: 29388346
[TBL] [Abstract][Full Text] [Related]
10. Cyclosporine inhibition of hepatic and intestinal CYP3A4, uptake and efflux transporters: application of PBPK modeling in the assessment of drug-drug interaction potential.
Gertz M; Cartwright CM; Hobbs MJ; Kenworthy KE; Rowland M; Houston JB; Galetin A
Pharm Res; 2013 Mar; 30(3):761-80. PubMed ID: 23179780
[TBL] [Abstract][Full Text] [Related]
11. Analysis of the repaglinide concentration increase produced by gemfibrozil and itraconazole based on the inhibition of the hepatic uptake transporter and metabolic enzymes.
Kudo T; Hisaka A; Sugiyama Y; Ito K
Drug Metab Dispos; 2013 Feb; 41(2):362-71. PubMed ID: 23139378
[TBL] [Abstract][Full Text] [Related]
12. Physiologically based pharmacokinetic modeling to predict transporter-mediated clearance and distribution of pravastatin in humans.
Watanabe T; Kusuhara H; Maeda K; Shitara Y; Sugiyama Y
J Pharmacol Exp Ther; 2009 Feb; 328(2):652-62. PubMed ID: 19001154
[TBL] [Abstract][Full Text] [Related]
13. Physiologically Based Pharmacokinetic (PBPK) Modeling of Pitavastatin and Atorvastatin to Predict Drug-Drug Interactions (DDIs).
Duan P; Zhao P; Zhang L
Eur J Drug Metab Pharmacokinet; 2017 Aug; 42(4):689-705. PubMed ID: 27858342
[TBL] [Abstract][Full Text] [Related]
14. Quantitative Analysis of Complex Drug-Drug Interactions between Cerivastatin and Metabolism/Transport Inhibitors Using Physiologically Based Pharmacokinetic Modeling.
Yao Y; Toshimoto K; Kim SJ; Yoshikado T; Sugiyama Y
Drug Metab Dispos; 2018 Jul; 46(7):924-933. PubMed ID: 29712725
[TBL] [Abstract][Full Text] [Related]
15. Quantitative Analyses of Hepatic OATP-Mediated Interactions Between Statins and Inhibitors Using PBPK Modeling With a Parameter Optimization Method.
Yoshikado T; Yoshida K; Kotani N; Nakada T; Asaumi R; Toshimoto K; Maeda K; Kusuhara H; Sugiyama Y
Clin Pharmacol Ther; 2016 Nov; 100(5):513-523. PubMed ID: 27170342
[TBL] [Abstract][Full Text] [Related]
16. Substrate-dependent drug-drug interactions between gemfibrozil, fluvastatin and other organic anion-transporting peptide (OATP) substrates on OATP1B1, OATP2B1, and OATP1B3.
Noé J; Portmann R; Brun ME; Funk C
Drug Metab Dispos; 2007 Aug; 35(8):1308-14. PubMed ID: 17470528
[TBL] [Abstract][Full Text] [Related]
17. Characterization of Long-Lasting Oatp Inhibition by Typical Inhibitor Cyclosporine A and In Vitro-In Vivo Discrepancy in Its Drug Interaction Potential in Rats.
Taguchi T; Masuo Y; Kogi T; Nakamichi N; Kato Y
J Pharm Sci; 2016 Jul; 105(7):2231-9. PubMed ID: 27290622
[TBL] [Abstract][Full Text] [Related]
18. The role of hepatic transport and metabolism in the interactions between pravastatin or repaglinide and two rOatp inhibitors in rats.
Badolo L; Bundgaard C; Garmer M; Jensen B
Eur J Pharm Sci; 2013 Jul; 49(4):767-72. PubMed ID: 23648783
[TBL] [Abstract][Full Text] [Related]
19. Mechanistic Evaluation of the Complex Drug-Drug Interactions of Maraviroc: Contribution of Cytochrome P450 3A, P-Glycoprotein and Organic Anion Transporting Polypeptide 1B1.
Kimoto E; Vourvahis M; Scialis RJ; Eng H; Rodrigues AD; Varma MVS
Drug Metab Dispos; 2019 May; 47(5):493-503. PubMed ID: 30862625
[TBL] [Abstract][Full Text] [Related]
20. Semi-mechanistic physiologically-based pharmacokinetic modeling of clinical glibenclamide pharmacokinetics and drug-drug-interactions.
Greupink R; Schreurs M; Benne MS; Huisman MT; Russel FG
Eur J Pharm Sci; 2013 Aug; 49(5):819-28. PubMed ID: 23806476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
